STAT August 8, 2024
Why did Novo Nordisk pull its paperwork to expand the use of Wegovy for a common type of heart failure? How will we know if the the government gets a good deal in the first round of drug pricing negotiations? And has Allison thought about anything other than venture capital for the last couple of months?
We discuss all that and more on this week’s episode of “The Readout LOUD.” STAT’s Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1. We also cover the latest news in the life sciences including the merger of AI...